The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LAPIS: Randomized phase 3 trial of chemotherapy (CTX) with and without pamrevlumab (PAM) for locally advanced pancreatic cancer (LAPC).
 
Vincent Picozzi
Stock and Other Ownership Interests - Amgen; Cigna; Iovance Biotherapeutics; Johnson & Johnson; McKesson; Thermo Fisher Scientific
Consulting or Advisory Role - TriSalus Life Sciences
Research Funding - Abbvie; Amal Therapeutics; Astellas Pharma; FibroGen; Ipsen; NGM Biopharmaceuticals; Novocure
 
Khurum Khan
Honoraria - Bayer; Bristol Myers Squibb Foundation; Nouscom; SERVIER; Takeda
Consulting or Advisory Role - Bayer Health
Research Funding - Nouscom
 
Pascal Hammel
Consulting or Advisory Role - AstraZeneca (Inst); ERYTECH Pharma (Inst); IPSEN (Inst); Mylan; Rafael Pharmaceuticals; Revolution Medicines; Servier/Pfizer; VECT-HORUS
Speakers' Bureau - AstraZeneca; Mylan; SERVIER
Research Funding - AstraZeneca (Inst); Celgene (Inst); ERYTECH Pharma (Inst); Halozyme (Inst)
Travel, Accommodations, Expenses - Halozyme; Ipsen; Pfizer/EMD Serono; Shire; Vect-Horus
 
Michele Reni
Consulting or Advisory Role - BMS Italy; LEO Pharma; Viatris
 
Daniel Lin
Stock and Other Ownership Interests - BioNano Genomics
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis; Exelixis; Exelixis/Ipsen
 
Woo Jin Lee
No Relationships to Disclose
 
Roberto Pazo Cid
Consulting or Advisory Role - Astellas Pharma; AstraZeneca Spain; Bristol-Myers Squibb/Celgene; Eisai Europe; Ipsen; Roche; SERVIER
Speakers' Bureau - Astellas Pharma; AstraZeneca Spain; BMS GmbH & Co. KG; SERVIER
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Lilly; Roche/Genentech
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Autem Medical; Delcath Systems; Elevar Therapeutics; Histosonics; Incyte; Ipsen; Jazz Pharmaceuticals; Lynx Group; Rafael Pharmaceuticals; SERVIER; Taiho Oncology
Research Funding - Actuate Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Elicio Therapeutics (Inst); Esanik (Inst); Exelixis (Inst); FibroGen (Inst); Ipsen (Inst); MedImmune (Inst); Pancreatic Cancer Action Network (Inst); Rafael Pharmaceuticals (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); SERVIER (Inst); Syros Pharmaceuticals (Inst); TransThera Biosciences (Inst)
Travel, Accommodations, Expenses - ASCO; Lynx Group
Other Relationship - Rafael Pharmaceuticals (Inst)
 
Andres Munoz Martin
Consulting or Advisory Role - Celgene/Bristol-Myers Squibb; Daiichi Sankyo; Lee's Pharmaceutical; Pfizer; Sanofi
Speakers' Bureau - Bayer; Menarini; ROVI; Stada
Research Funding - Celgene/Bristol-Myers Squibb; Lee's Pharmaceutical; ROVI; Sanofi
Patents, Royalties, Other Intellectual Property - Risk assessment model VTE in cancer
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck Serono; Pfizer; Roche; SERVIER
 
Jianjun Liu
Employment - FibroGen
Stock and Other Ownership Interests - FibroGen; Karyopharm Therapeutics
 
Ende Zhao
Employment - FibroGen
Stock and Other Ownership Interests - FibroGen
Travel, Accommodations, Expenses - FibroGen
 
Ewa Carrier
Employment - FibroGen
Stock and Other Ownership Interests - FibroGen
Consulting or Advisory Role - Calidi Biotherapeutics
Research Funding - FibroGen
Patents, Royalties, Other Intellectual Property - FibroGen
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Amgen; Aptitude Health; Arcus Biosciences; AstraZeneca; Basilea; Baxter; BioLineRX; Boehringer Ingelheim; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Novocure; Paraxel; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Taiho / Keylates; Zymeworks
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER